Restricted accessResearch articleFirst published online 2015-02
Modulation of Interferon Activity-Associated Soluble Molecules by Appendicitis and Appendectomy Limits Colitis–Identification of Novel Anti-Colitic Targets
The therapeutic efficacy of interferons (IFNs) in ulcerative colitis is minimal. However, IFN activity-associated molecules have been inadequately investigated. Appendicitis and appendectomy (AA), when done while young, protect against colitis development later. Our novel murine AA model protects against colitis. This therapeutic target-identifying study enumerates IFN activity-associated molecules involved in this protection. Mice with 2 laparotomies were controls (sham-sham/SS). Distal colons were harvested (4 AA-group colons and 4 SS-group colons). Microarray-analysis/reverse transcriptase–polymerase chain reaction-validation was done from RNA from each (3-days/28-days-post-AA). Gene set enrichment analysis (GSEA) software was used to analyze distal colonic gene sets associated with 46 IFN activity-related genes. More AA-upregulated gene sets were associated with IFIT1, IFIT2, IFIT3, IRF7, IFI35, and IFI44 (False Discovery Rate-FDR <5% and P<0.001), although only IFIT1, IFIT2, IFIT3, and IFI44 showed individual gene upregulation (P<0.05). More AA-downregulated gene sets were associated with IRF1, IRF2, IRF4, IRF8, IRF9, IRF2BP1, IFRD1, IFRD2, and IFIH1 (FDR <5%/P<0.001); although only IRF2BP1 showed individual gene downregulation (P<0.05). There was significant upregulation (P<0.05) of IFNZ; and downregulation of IRF2BP2 and IFI30, despite no major associated GSEA differences. IFIT1, IFIT2, IFIT3, and IFI44, with profound AA-induced individual/GSEA upregulation, and their immunomodulatory/ antiproliferative activity, are the best molecules to investigate therapeutic potential. IRF4, IRF8, IRF2BP1, IFRD1, and IFRD2, owing to their profound AA-induced gene set downregulation, and because of their diverse lymphocytic activity, are good targets to competitively inhibit or to treat with exogenous products in knockout animals.
Get full access to this article
View all access options for this article.
References
1.
AddissDG, ShafferN, FowlerBS, TauxeRV. 1990. The epidemiology of appendicitis and appendectomy in the United States. Am J Epidemiol, 132(5):910–925.
2.
BangeFC, VogelU, FlohrT, KiekenbeckM, DeneckeB, BottgerEC. 1994. IFP 35 is an interferon-induced leucine zipper protein that undergoes interferon-regulated cellular redistribution. J Biol Chem, 269(2):1091–1098.
BoehmU, KlampT, GrootM, HowardJC. 1997. Cellular responses to interferon-gamma. Annu Rev Immunol, 15:749–795.
5.
BrazmaA, HingampP, QuackenbushJ, SherlockG, SpellmanP, StoeckertC, AachJ, AnsorgeW, BallCA, CaustonHC, GaasterlandT, GlenissonP, HolstegeFC, KimIF, MarkowitzV, MateseJC, ParkinsonH, RobinsonA, SarkansU, Schulze-KremerS, StewartJ, TaylorR, ViloJ, VingronM. 2001. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet, 29(4):365–371.
6.
CheluvappaR. 2014. A novel model of appendicitis and appendectomy to investigate inflammatory bowel disease pathogenesis and remediation. Biol Proced Online, 16(10).
7.
CheluvappaR, LuoAS, GrimmMC. 2014a. Autophagy suppression by appendicitis and appendectomy protects against colitis. Inflamm Bowel Dis, 20(5):847–855.
8.
CheluvappaR, LuoAS, GrimmMC. 2014b. T helper type 17 pathway suppression by appendicitis and appendectomy protects against colitis. Clin Exp Immunol, 175(2):316–322.
9.
CheluvappaR, LuoAS, PalmerC, GrimmMC. 2011. Protective pathways against colitis mediated by appendicitis and appendectomy. Clin Exp Immunol, 165(3):393–400.
10.
ChildsKS, GoodbournS. 2003. Identification of novel co-repressor molecules for Interferon Regulatory Factor-2. Nucleic Acids Res, 31(12):3016–3026.
11.
DaltonDK, Pitts-MeekS, KeshavS, FigariIS, BradleyA, StewartTA. 1993. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science, 259(5102):1739–1742.
12.
DaneseS, AngelucciE, MalesciA, CaprilliR. 2008. Biological agents for ulcerative colitis: hypes and hopes. Med Res Rev, 28(2):201–218.
13.
FarkasSA, HornungM, SattlerC, SteinbauerM, AnthuberM, ObermeierF, HerfarthH, SchlittHJ, GeisslerEK. 2005. Preferential migration of CD62L cells into the appendix in mice with experimental chronic colitis. Eur Surg Res, 37(2):115–122.
FrantzAL, BrunoME, RogierEW, TunaH, CohenDA, BondadaS, ChelvarajanRL, BrandonJA, JenningsCD, KaetzelCS. 2012. Multifactorial patterns of gene expression in colonic epithelial cells predict disease phenotypes in experimental colitis. Inflamm Bowel Dis, 18(11):2138–2148.
16.
GillyM, WallR. 1992. The IRG-47 gene is IFN-gamma induced in B cells and encodes a protein with GTP-binding motifs. J Immunol, 148(10):3275–3281.
17.
GuoJ, HuiDJ, MerrickWC, SenGC. 2000a. A new pathway of translational regulation mediated by eukaryotic initiation factor 3. EMBO J, 19(24):6891–6899.
18.
GuoJ, PetersKL, SenGC. 2000b. Induction of the human protein P56 by interferon, double-stranded RNA, or virus infection. Virology, 267(2):209–219.
19.
HallenLC, BurkiY, EbelingM, BrogerC, SiegristF, Oroszlan-SzovikK, BohrmannB, CertaU, FoserS. 2007. Antiproliferative activity of the human IFN-alpha-inducible protein IFI44. J Interferon Cytokine Res, 27(8):675–680.
20.
HansenJJ, HoltL, SartorRB. 2009. Gene expression patterns in experimental colitis in IL-10-deficient mice. Inflamm Bowel Dis, 15(6):890–899.
21.
HommesDW, MikhajlovaTL, StoinovS, StimacD, VucelicB, LonovicsJ, ZakuciovaM, D'HaensG, Van AsscheG, BaS, LeeS, PearceT. 2006. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut, 55(8):1131–1137.
22.
HondaK, TaniguchiT. 2006. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol, 6(9):644–658.
23.
HuangS, HendriksW, AlthageA, HemmiS, BluethmannH, KamijoR, VilcekJ, ZinkernagelRM, AguetM. 1993. Immune response in mice that lack the interferon-gamma receptor. Science, 259(5102):1742–1745.
IsaacsA, LindenmannJ. 1957. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci, 147(927):258–267.
26.
KoutroubakisIE, VlachonikolisIG, KouroumalisEA. 2002. Role of appendicitis and appendectomy in the pathogenesis of ulcerative colitis: a critical review. Inflamm Bowel Dis, 8(4):277–286.
27.
KrieglsteinCF, CerwinkaWH, LarouxFS, GrishamMB, SchurmannG, BruwerM, GrangerDN. 2001. Role of appendix and spleen in experimental colitis. J Surg Res, 101(2):166–175.
28.
LiY, LiC, XueP, ZhongB, MaoAP, RanY, ChenH, WangYY, YangF, ShuHB. 2009. ISG56 is a negative-feedback regulator of virus-triggered signaling and cellular antiviral response. Proc Natl Acad Sci U S A, 106(19):7945–7950.
29.
LohoffM, MakTW. 2005. Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat Rev Immunol, 5(2):125–135.
30.
LuoAS, NgWSW, GrimmMC. 2009. Localisation and phenotype of protective lymphocytes in the colon of mice following appendicitis. J Gastroenterol Hepatol, 24Suppl. 2:A314
31.
MacMickingJ, XieQW, NathanC. 1997. Nitric oxide and macrophage function. Annu Rev Immunol, 15:323–350.
32.
MarudanayagamR, WilliamsGT, ReesBI. 2006. Review of the pathological results of 2660 appendicectomy specimens. J Gastroenterol, 41(8):745–749.
33.
MizoguchiA, MizoguchiE, ChibaC, SpiekermannGM, TonegawaS, Nagler-AndersonC, BhanAK. 1996. Cytokine imbalance and autoantibody production in T cell receptor-alpha mutant mice with inflammatory bowel disease. J Exp Med, 183(3):847–856.
34.
MouraR, AraujoJ, GuimaraesR, CrovellaS, BrandaoL. 2013. Interferon induced with helicase C domain 1 (IFIH1): trends on helicase domain and type 1 diabetes onset. Gene, 516(1):66–68.
35.
OhtekiT, YoshidaH, MatsuyamaT, DuncanGS, MakTW, OhashiPS. 1998. The transcription factor interferon regulatory factor 1 (IRF-1) is important during the maturation of natural killer 1.1+T cell receptor-alpha/beta+(NK1+T) cells, natural killer cells, and intestinal intraepithelial T cells. J Exp Med, 187(6):967–972.
36.
OritaniK, KanakuraY. 2005. IFN-zeta/limitin: a member of type I IFN with mild lympho-myelosuppression. J Cell Mol Med, 9(2):244–254.
37.
PestkaS, KrauseCD, WalterMR. 2004. Interferons, interferon-like cytokines, and their receptors. Immunol Rev, 202:8–32.
38.
PestkaS, LangerJA, ZoonKC, SamuelCE. 1987. Interferons and their actions. Annu Rev Biochem, 56:727–777.
39.
ReinischW, de VilliersW, BeneL, SimonL, RaczI, KatzS, AltorjayI, FeaganB, RiffD, BernsteinCN, HommesD, RutgeertsP, CortotA, GaspariM, ChengM, PearceT, SandsBE. 2010. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis, 16(2):233–242.
40.
ReisLF, HaradaH, WolchokJD, TaniguchiT, VilcekJ. 1992. Critical role of a common transcription factor, IRF-1, in the regulation of IFN-beta and IFN-inducible genes. EMBO J, 11(1):185–193.
41.
SainathanSK, BishnupuriKS, AdenK, LuoQ, HouchenCW, AnantS, DieckgraefeBK. 2012. Toll-like receptor-7 ligand Imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis. Inflamm Bowel Dis, 18(5):955–967.
42.
SeowCH, BenchimolEI, GriffithsAM, SteinhartAH. 2008. Type I interferons for induction of remission in ulcerative colitis. Cochrane Database Syst Rev, (3):CD006790
43.
StarkGR, KerrIM, WilliamsBR, SilvermanRH, SchreiberRD. 1998. How cells respond to interferons. Annu Rev Biochem, 67:227–264.
44.
StoreyJD, TibshiraniR. 2003. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A, 100(16):9440–9445.
45.
SubramanianA, TamayoP, MoothaVK, MukherjeeS, EbertBL, GilletteMA, PaulovichA, PomeroySL, GolubTR, LanderES, MesirovJP. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 102(43):15545–15550.
46.
te VeldeAA, de KortF, SterrenburgE, PronkI, ten KateFJ, HommesDW, van DeventerSJ. 2007. Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis, 13(3):325–330.
47.
Watson NgWS, HampartzoumianT, LloydAR, GrimmMC. 2007. A murine model of appendicitis and the impact of inflammation on appendiceal lymphocyte constituents. Clin Exp Immunol, 150(1):169–178.
48.
WestLC, CresswellP. 2013. Expanding roles for GILT in immunity. Curr Opin Immunol, 25(1):103–108.
49.
XiaoS, LiD, ZhuHQ, SongMG, PanXR, JiaPM, PengLL, DouAX, ChenGQ, ChenSJ, ChenZ, TongJH. 2006. RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. Proc Natl Acad Sci U S A, 103(44):16448–16453.
50.
YorkIA, RockKL. 1996. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol, 14:369–396.
51.
ZhaoGN, JiangDS, LiH. 2014. Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease. Biochim Biophys Acta. [Epub ahead of print]; DOI: 10.1016/j.bbadis.2014.04.030
